問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Others-Department of Oncology

Digestive System Department

Division of General Surgery

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Taipei Veterans General Hospital

更新時間：2024-06-04

顏家瑞Yen, Chia-Jui
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

  • yencj@mail.ncku.edu.tw

Recruiting Trial

165Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏家瑞

List

336Cases

2018-10-01 - 2022-12-31

Phase II

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

  • Condition/Disease

    Nasopharyngeal Carcinoma

  • Test Drug

    Pembrolizumab (MK3475)

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2021-03-02 - 2024-06-16

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-03-01 - 2019-12-31

Phase III

A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

  • Condition/Disease

    Advanced or Metastatic Gastric Cancer

  • Test Drug

    Apatinib

Participate Sites
10Sites

Terminated8Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2019-08-07 - 2023-04-30

Phase III

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial

  • Condition/Disease

    Cholangiocarcinoma

  • Test Drug

    Infigratinib(BGJ398)

Participate Sites
8Sites

Recruiting8Sites

2020-01-31 - 2023-10-03

Phase II/III

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    GSK3359609

Participate Sites
7Sites

Recruiting7Sites

2018-03-01 - 2022-12-13

Phase III

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN).

  • Condition/Disease

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • Test Drug

    Nivolumab

Participate Sites
7Sites

Not yet recruiting1Sites

Terminated3Sites

謝清昀
China Medical University Hospital-Taipei

未分科

2018-12-18 - 2021-12-31

Phase I

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ASP8374(PTZ-201)

Participate Sites
4Sites

Recruiting3Sites

邱昌芳
China Medical University Hospital-Taipei

未分科

2017-06-02 - 2020-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

李重賓
Taipei Veterans General Hospital

Digestive System Department

2017-01-06 - 2022-01-05

Phase III

ONO-4538 Phase III Study A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
10Sites

Terminated8Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 21 22 23 24 25 34
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB